

**Net performance<sup>1</sup> (%)**

	1 month	3 month	CYTD	1 year	3 year p.a.	5 year p.a.	Inception p.a.
Fund	0.1	2.7	2.7	7.1	3.3	2.1	6.3

Returns greater than 1 year are annualised. Past performance is no indication of future performance. Inception is 31 August 2011.

The Fund was previously known as the Premium Asia Income Fund. Antipodes Partners Limited has appointed Value Partners under a sub-investment manager agreement to undertake portfolio management of the Fund. Value Partners have been the Investment Manager of this Fund since its inception. Please note the name of the Antipodes Emerging Market Debt Fund changed from the Asia Income Fund on 31 March 2025.

**Sector exposure<sup>2</sup> (%)**

Sector	Long
Real Estate	18.0
Banks	10.1
Consumer Services	10.0
Utilities	9.3
Materials	7.6
Diversified Financials	7.0
Energy	6.5
Insurance	5.7
Retailing	5.1
Capital Goods	3.7
Transportation	2.9
Commercial & Professional Services	1.9
Consumer Durables & Apparel	1.6
Telecommunication Services	1.1
Semiconductors & Semiconductor Equipment	0.8
Food, Beverage & Tobacco	0.4
Technology Hardware & Equipment	0.4
Pharmaceuticals, Biotechnology & Life Sciences	0.4

**Top 10 holdings<sup>3</sup> (%)**

Name	Country	Weight
China Oil & Gas	China/Hong Kong	3.0
PCPD Capital	China/Hong Kong	2.7
Bukit Makmur Mandiri	Indonesia	2.7
GLP China	China/Hong Kong	2.3
Champion Path	China/HK	2.2
Sammaan Capital	India	2.1
Rakuten Group	Japan	2.0
Kawasan Industri Jababeka	Indonesia	2.0
PCGI Intermediate	China/Hong Kong	2.0
Bank Negara Indonesia	Indonesia	1.8

**Regional exposure<sup>3,4,5</sup> (%)**

Region	Long
<b>Developed Asia</b>	<b>10.1</b>
- Japan	9.3
- Korea	0.4
- Taiwan	0.4
<b>Developing Asia</b>	<b>79.5</b>
- China/HK	49.9
- Indonesia	12.3
- India	11.8
- Rest EM Asia	3.3
- Thailand	1.6
<b>- Singapore</b>	<b>0.6</b>
<b>Rest of World</b>	<b>5.3</b>
<b>Cash &amp; Hedges</b>	<b>5.1</b>

**Portfolio characteristics and product composition (%)**

Portfolio Characteristics	Value
Cash Yield	6.85%
Yield to Maturity	10.09%
Time to maturity, years	4.05
Modified duration, years	3.13
Number of bond positions	104
Product Composition	Value
Straight Bond	91.2
Convertible Bond	3.7
Cash	4.6
FX Hedges	0.5

## Fund facts

Characteristics	
Investment manager	Antipodes Partners Limited
Sub investment manager	Value Partners
Inception date	Aug-11
Management Fee	1.13% p.a.
Performance Fee	Nil
Risk/Return profile	Medium
Buy/Sell spread	±0.3%
Minimum Investment	A\$25,000
Distributions	Quarterly

## Fund features

- The Fund seeks current income and some capital appreciation by investing mostly in a diversified portfolio of high yielding, sub investment grade securities and non-rated securities across a range of markets in Asia and the Middle East.
- Flexibility to hedge for risk management purposes:
  - Derivatives may be used to hedge existing exposures or to gain economic exposure.
  - The Fund is expected to be hedged in Australian dollars within a range of 0% to 100% of the Fund's NAV.
  - Leverage not permitted.
- This product is likely to be appropriate for investors who are looking for an investment with the objective to generate regular income with some long-term capital growth.

## Fund ratings



## Further information

- 1300 010 311
- invest@antipodes.com

## Australia Head Office

Antipodes Partners Limited  
Level 25, Australia Square  
Tower, 264 George Street  
Sydney NSW 2000

## UK Office

Antipodes Partners Limited  
Suite 823  
125 Old Broad Street  
London EC2N 1AR UK

1 Based on net returns in AUD

2 GICS classification

3 Call (put) options represented as the current option value (delta adjusted exposure)

4 Antipodes classification

5 Where possible, regions, countries and currencies classified on a look through basis

6 All metrics are based on gross of fee returns in AUD terms since inception. The upside/downside capture ratio is the percentage of benchmark performance captured by the fund during months that the benchmark is up/down. Standard deviation is a measure of risk with a smaller figure indicating lower return volatility. The Sharpe ratio measures returns on a risk adjusted basis with a figure > 1 indicating a higher return than the benchmark for the respective levels of return volatility.

## Disclaimer

Equity Trustees Limited ("Equity Trustees") (ABN 46 004 031 298), AFSL 240975, is the Responsible Entity for the Antipodes Emerging Market Debt Fund (ARSN 151 270 423) ("the Fund"). Equity Trustees is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a publicly listed company on the Australian Securities Exchange (ASX: EQT).

This communication has been prepared by Antipodes Partners Limited ('Antipodes') (ABN 29 602 042 035, AFSL 481 580) to provide you with general information only. In preparing this communication, we did not take into account the investment objectives, financial situation or particular needs of any particular person. It is not intended to take the place of professional advice and you should not take action on specific issues in reliance on this information. Neither Antipodes, Equity Trustees nor any of its related parties, their employees or directors, provide warranty of accuracy or reliability in relation to such information or accepts any liability to any person who relies on it. Past performance should not be taken as an indicator of future performance. You should obtain a copy of the Product Disclosure Statement before making a decision about whether to invest in this product.

Antipodes Emerging Market Debt Fund's Target Market Determination is available [here](#).

A Target Market Determination is a document which is required to be made available from 5 October 2021. It describes who this financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where the Target Market Determination for this financial product may need to be reviewed.

The Lonsac Rating (assigned as follows: Antipodes Emerging Market Debt Fund – August 2024) presented in this document are published by Lonsac Research presented in this document are published by Lonsac Research Pty Ltd ABN 11 151 658 561 AFSL 421445. The Ratings are limited to "General Advice" (as defined in the Corporations Act 2001 (Cth)) and based solely on consideration of the investment merits of the financial products. Past performance information is for illustrative purposes only and is not indicative of future performance. They are not a recommendation to purchase, sell or hold Antipodes products, and you should seek independent financial advice before investing in these products. The Ratings are subject to change without notice and Lonsac assumes no obligation to update the relevant documents following publication. Lonsac receives a fee from the Fund Manager for researching the products using comprehensive and objective criteria. For further information regarding Lonsac's Ratings methodology, please refer to our website at <https://www.lonsac.com.au/>.

The rating contained on this page is issued by SQM Research Pty Ltd ABN 93 122 592 036 AFSL 421913. SQM Research is an investment research firm that undertakes research on investment products exclusively for its wholesale clients, utilising a proprietary review and star rating system. The SQM Research star rating system is of a general nature and does not take into account the particular circumstances or needs of any specific person. The rating may be subject to change at any time. Only licensed financial advisers may use the SQM Research star rating system in determining whether an investment is appropriate to a person's particular circumstances or needs. You should read the product disclosure statement and consult a licensed financial adviser before making an investment decision in relation to this investment product. SQM Research receives a fee from the Fund Manager for the research and rating of the managed investment scheme.